Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America Health Times.
Press releases published on May 16, 2025
SRx Health Solutions Further Diversifies Treasury Strategy with Purchase of Ethereum
GlobeNewswire
·
May 16, 2025
TAMPA, Fla., May 16, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”), a leading global health and wellness company, today announced further diversifying its treasury strategy with the purchase of Ethereum (ETH). …
Psychemedics Named “Most Innovative Drug Testing Company of the Year”
GlobeNewswire
·
May 16, 2025
DALLAS, May 16, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, the world’s leading provider of hair drug testing, is proud to announce it has been named “Most Innovative Drug Testing Company of the Year” by Acquisition International Magazine as part of …
Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of…
GlobeNewswire
·
May 16, 2025
PALO ALTO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the …
BON Announces The Launch Of Its Postbiotic Hypoglycemic Patented Ingredient Product Series And Its Cooperation Agreement
GlobeNewswire
·
May 16, 2025
XI’AN, China, May 16, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, announced an exclusive cooperation agreement with …
Medicines for Poland: Europe Faces a Critical Choice on Medicines and Market Reform
GlobeNewswire
·
May 16, 2025
WARSAW, Poland, May 16, 2025 (GLOBE NEWSWIRE) -- Member States are nearing the end of discussions on EU pharmaceutical reform to ensure affordable medicines and support EU manufacturing in Europe. This will enhance the Union’s strategic resilience and …
Orthopedic Devices Market worth US$68.51 billion by 2030 with 4.8% CAGR | MarketsandMarkets™.
GlobeNewswire
·
May 16, 2025
Delray Beach, FL, May 16, 2025 (GLOBE NEWSWIRE) -- The global orthopedic devices market , valued at US$49.63 billion in 2023, is forecasted to grow at a robust CAGR of 4.8%, reaching US$51.61 billion in 2024 and an impressive US$68.51 billion by 2030. The …
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split
GlobeNewswire
·
May 16, 2025
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 16, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound …
Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study
GlobeNewswire
·
May 16, 2025
Company intends to provide an interim read out by the end of summer 2025 Top-line results anticipated in Q4 2025; study on track to support U.S. pivotal trial initiation in 2026 BERKELEY, Calif. and MAINZ, Germany, May 16, 2025 (GLOBE NEWSWIRE) -- Mainz …
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
May 16, 2025
SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and …
Vivex Biologics, Inc. Executive Chair Nominated for Ernst & Young LLP Entrepreneur of the Year® 2025 Florida Award
GlobeNewswire
·
May 16, 2025
MIAMI, May 16, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, Inc., a leader in developing and delivering innovative allografts, today announced the company’s Executive Chairman, John A. McCallum, has been selected as a finalist in the prestigious Ernst …
Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day
GlobeNewswire
·
May 16, 2025
WOBURN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will host a conference call on Thursday, May …
Spectral Medical to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference
GlobeNewswire
·
May 16, 2025
TORONTO, May 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that management will participate in a …
Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates
GlobeNewswire
·
May 16, 2025
WARRINGTON, Pa., May 16, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies …
Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting
GlobeNewswire
·
May 16, 2025
Company Urges Stockholders to Vote ‘FOR’ Reverse Stock Split Proposal at Upcoming Annual Meeting to Avoid Nasdaq Delisting Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Support Proposal #2 SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE …
Paratek Pharmaceuticals to Present Clinical Data on NUZYRA® (omadacycline) at the American Thoracic Society (ATS) 2025 International Conference
GlobeNewswire
·
May 16, 2025
First conference presentations for: Phase 2b study for nontuberculous mycobacterial pulmonary disease (NTM PD) caused by Mycobacterium abscessus complex (MABc) Phase 3 OPTIC-2 study in moderate-to-severe community-acquired bacterial pneumonia (CABP) BOSTON …
BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)
GlobeNewswire
·
May 16, 2025
RESEARCH TRIANGLE PARK, N.C., May 16, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO® (berotralstat) in adolescents and people with severe HAE showing …
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
·
May 16, 2025
WATERTOWN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that …
First Steroid Cycle: Best Steroids for Muscle Growth (Before And After Result), Steroids for Beginners - By CrazyBulk USA
GlobeNewswire
·
May 16, 2025
New York City, NY, May 16, 2025 (GLOBE NEWSWIRE) -- Initiating the first steroid cycle as a new bodybuilder may be thrilling yet terrifying. Despite all the information and diverse counsel obtainable over the internet, most new bodybuilders are undecided …
Thyroid Support Under Review: Best Thyroid Support Supplements For Thyroid Health & Healthy Thyroid Hormone Production
GlobeNewswire
·
May 16, 2025
Richmond, Virginia, May 16, 2025 (GLOBE NEWSWIRE) -- The thyroid gland is a little organ in our body but a very fascinating one. It sits at the bottom of every human body‘s neck. The shape of the thyroid line resembles that of a butterfly and its healthy …
CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American…
GlobeNewswire
·
May 16, 2025
Haploinsufficient SYNGAP1 mice treated with CMP-SYNGAP-01 demonstrated an increase in SYNGAP1 protein levels; treatment rescued multiple SYNGAP1-dependent behavioral phenotypes CMP-SYNGAP-01 administration led to a significant increase in SYNGAP1 protein …